Amina Abulimiti
Postdoctoral Research Scientist
I’m currently working on an interdisciplinary, multi-centre project with Professor Richard Wade-Martins (University of Oxford) and Professor Jody Mason (University of Bath). My focus is on developing and testing novel peptides that target alpha-synuclein aggregation, a key pathological feature of Parkinson’s disease (PD), with the aim of reducing aggregation and alleviating PD-related cellular phenotypes in human patient iPSC-derived dopaminergic neurons as a potential therapeutic strategy. Before joining the Wade-Martins group, I completed my PhD at Imperial College London, where I investigated how dysregulation of mitochondrial metabolic efficiency contributes to the selective vulnerability of dopaminergic neurons in PD, using post-mortem human brain tissue and primary mesencephalic neurons.